BioCardia Receives Formal Nasdaq Delisting Non-Compliance Notice
BCDA sits 18% above its 52-week low of $1 on light trading volume (0.2× avg).
Summary
BioCardia received a formal Nasdaq notice for failing to meet minimum stockholders' equity, intensifying delisting risk for the cash-strapped company.
Key Events · Corporate Governance and Compliance · BCDA
-
Nasdaq Non-Compliance Notice
BioCardia received a formal notice from Nasdaq on April 10, 2026, for non-compliance with the minimum stockholders' equity requirement of $2.5 million, reporting only $895,000 as of December 31, 2025.
-
Delisting Risk Intensified
This notice formalizes the delisting risk previously highlighted in the company's recent 10-K, which also indicated a cash runway only until May 2026.
-
Compliance Plan Required
The company has until May 25, 2026, to submit a plan to regain compliance, with a potential extension of up to 180 days if accepted.
Analysis · BCDA · Life Sciences
This 8-K confirms BioCardia's receipt of a formal notice from Nasdaq regarding non-compliance with the minimum stockholders' equity requirement. This event was anticipated by the company's recent 10-K, which highlighted severe liquidity issues and delisting risk. The notice puts additional pressure on the company, which has a cash runway only until May 2026. While the company intends to submit a compliance plan, the formal notice underscores the precarious financial position and the significant risk of eventual delisting, which could severely impact investor confidence and access to capital.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 42.2% of the 325 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.39%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BCDA was trading at $1.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13M. The 52-week trading range was $1.00 to $3.20. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.